Abstract
Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care.
Keywords: Early diagnosis, genomics, pancreatic cancer, postgenomics medicine, targeted oncopharmacology
Current Pharmacogenomics and Personalized Medicine
Title: Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Volume: 8 Issue: 1
Author(s): A. S. Strimpakos, C. Hoimes, K. N. Syrigos and M. W. Saif
Affiliation:
Keywords: Early diagnosis, genomics, pancreatic cancer, postgenomics medicine, targeted oncopharmacology
Abstract: Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care.
Export Options
About this article
Cite this article as:
S. Strimpakos A., Hoimes C., N. Syrigos K. and W. Saif M., Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?, Current Pharmacogenomics and Personalized Medicine 2010; 8 (1) . https://dx.doi.org/10.2174/1875692111008010073
DOI https://dx.doi.org/10.2174/1875692111008010073 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Properties and Recent Advantages of N,N’-dialkylimidazolium-ion Liquids Application in Electrochemistry
Current Analytical Chemistry Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines
Current Topics in Medicinal Chemistry Electrochemical Immunosensors Based on Nanostructured Materials for Sensing of Prostate-Specific Antigen: A Review
Current Medicinal Chemistry Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Microwave–assisted Synthesis of Chalcones, Flavanones and 2- pyrazolines: Theoretical and Experimental Study
Letters in Organic Chemistry HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions
Current Cancer Drug Targets Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology